Skip to content

US · YARW · BIOTECHNOLOGY

Yarrow Bioscience Inc (YARW) intrinsic value and stock valuation

$12.90as of 2026-11-21 · Mkt cap 648.29K

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Yarrow Bioscience Inc DCF and intrinsic value

InvestorsCraft values YARW with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from YARW’s statements →

Yarrow Bioscience Inc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New Haven, CT 06513 yarrowbioscience.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$570K-51.4% 5y CAGRd
20152025
Net income
-$-26.48M
20152025
Free cash flow
-$-33.12M
20152025
Total equity
$27.8M-5.8% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$570K$500K$420K$480K$930K
Operating income-$-29.75M-$-43.64M-$-29.26M-$-34.3M-$-38.91M
Net income-$-26.48M-$-39.83M-$-28.45M-$-23.21M-$-73.33M
EPSd-$-1.32B-$-1.99B———
Operating cash flow-$-33.12M-$-33.97M-$-25.34M-$-29.2M-$-56.37M
Capital expenditure$0.00-$-120K$0.00$0.00$0.00
Free cash flow-$-33.12M-$-34.09M-$-25.34M-$-29.2M-$-56.37M
Total assets$30.2M$66.9M$97.7M$40.8M$67.1M
Total debt$0.00$100K$210K$0.00$350K
Net debt-$-24.03M-$-19.83M-$-30.41M-$-30.91M-$-41.9M
Total equity$27.8M$52.1M$88.7M$31.2M$48.6M
Cash and short-term investments$29M$61.5M$93.3M$30.9M$42.3M
Income statement
20252024202320222021
Revenue$570K$500K$420K$480K$930K
Cost of revenue$20K$0.00$0.00$0.00$0.00
Gross profit$550K$500K$420K$480K$930K
Research and development expenses$19.2M$31M$16.3M$18.4M$19.5M
Selling, general and administrative expenses$11.1M$13.2M$13.4M$16.4M$20.3M
Other expenses-$-20K$0.00$0.00$0.00$0.00
Operating expenses$30.3M$44.1M$29.7M$34.8M$39.8M
Cost and expenses$30.3M$44.1M$29.7M$34.8M$39.8M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$5.61M
Depreciation and amortization$0.00$0.00$0.00$70K$110K
Ebitda-$-26.73M-$-39.8M-$-27.87M-$-33.86M-$-38.04M
Operating income-$-29.75M-$-43.64M-$-29.26M-$-34.3M-$-38.91M
Total other income/expenses, net$3.02M$3.83M$1.39M$360K-$-4.85M
Income before tax-$-26.73M-$-39.8M-$-27.87M-$-33.93M-$-43.76M
Income tax expense$0.00$0.00$0.00$10K$450K
Net income-$-26.48M-$-39.83M-$-28.45M-$-23.21M-$-73.33M
Weighted average shares outstanding$20K$20K$0.00$0.00$0.00
Weighted average diluted shares outstanding$20K$20K$0.00$0.00$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$29M$61.5M$93.3M$30.9M$42.3M
Net receivables$0.00$0.00$0.00$5M$7.58M
Inventory$0.00$0.00$0.00$0.00$7.29M
Total current assets$30M$64.4M$96M$38.3M$63.2M
Property, plant and equipment, net$90K$210K$210K$0.00$350K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$150K$2.47M$1.72M$2.48M$3.86M
Total assets$30.2M$66.9M$97.7M$40.8M$67.1M
Accounts payable$1.04M$2.71M$1.66M$2.39M$6.51M
Short-term debt$0.00$100K$120K$0.00$350K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.4M$14.8M$7.54M$9.35M$18.4M
Long-term debt$0.00$0.00$100K$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$1.41M$210K$0.00
Capital lease obligations$0.00$100K$210K$0.00$350K
Total liabilities$2.4M$14.8M$8.95M$9.56M$18.4M
Common stock$0.00$0.00$0.00$0.00$10K
Retained earnings-$-757.65M-$-731.17M-$-691.34M-$-662.74M-$-639.52M
Accumulated other comprehensive income (loss)$0.00$20K$30K$0.00$0.00
Total equity$27.8M$52.1M$88.7M$31.2M$48.6M
Total investments$4.98M$41.6M$62.6M$0.00$0.00
Total debt$0.00$100K$210K$0.00$350K
Net debt-$-24.03M-$-19.83M-$-30.41M-$-30.91M-$-41.9M
Cash flow statement
20252024202320222021
Net income-$-26.74M-$-39.83M-$-28.45M-$-23.21M-$-73.33M
Depreciation and amortization$20K$0.00$0.00$70K$110K
Stock-based compensation$2.31M$3.3M$3.31M$4.3M$8.08M
Change in working capital-$-8.19M$5M$60K$2.28M$4.78M
Accounts receivable$4.21M-$-900K$410K$11.2M$7.71M
Inventory$0.00$0.00$0.00$100K$110K
Accounts payable-$-12.31M$6.01M-$-560K-$-8.68M-$-2.67M
Net cash provided by operating activities-$-33.12M-$-33.97M-$-25.34M-$-29.2M-$-56.37M
Investments in property, plant and equipment$0.00-$-120K$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$5M$15.7M$0.00
Net cash used for investing activities$37.4M$23.4M-$-57.35M$15.7M$1.03M
Common stock issued-$-140K$0.00$82.8M$1.47M$76M
Common stock repurchased$0.00-$-140K$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-140K-$-140K$82.4M$1.65M$39.8M
Net change in cash$4.1M-$-10.75M-$-300K-$-11.88M-$-15.56M
Cash at end of period$24M$19.9M$30.7M$31M$42.9M
Operating cash flow-$-33.12M-$-33.97M-$-25.34M-$-29.2M-$-56.37M
Capital expenditure$0.00-$-120K$0.00$0.00$0.00
Free cash flow-$-33.12M-$-34.09M-$-25.34M-$-29.2M-$-56.37M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Yarrow Bioscience Inc

        Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).

        CEO
        David Domzalski
        Employees
        10
        Beta
        2.01

        Explore

        Frequently asked questions

        What is the intrinsic value of Yarrow Bioscience Inc (YARW)?

        Yarrow Bioscience Inc (YARW) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is YARW undervalued?

        YARW trades at a price of $12.90 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.